Argentine hemorrhagic fever (AHF) is a po-strain Junin virus. This vaccine, Candid #1, which teatially lethal infection of humans recognized was found to be phenotypically stable after in among the inhabitants of the small, but econom-vitro passage, was significantly more attenuated ically important, humid pampas of northcentral for newborn mice and guinea pigs than XJ Clone Argentina. The etiologic agent, Junin virus, is a 3 (an early generation human vaccine), and promember of the family Arenaviridae. The virus is tected guinea pigs against lethal challenge with maintained in nature through chronic carriage in virulent Junin and Machupo virus strains. In adseveral species of cricetine rodent, primarily Cal-dition, preliminary neurovirulence testing indiomvs musculinus and C. laucha,'-Contamina-cated that this vaccine was safe by intracerebral tion with secreta and excreta of reservoir rodents, inoculation of rhesus macaques' (Barrera Oro J. through abrasions or inhalation of highly infecEddy G, unpublished data). tious aerosols, constitutes the principal means
The current study documents the safety and by which human infection occurs. ' immunogenicity of Candid #1 when adminisUntreated, mortality from AHF may approach tered by peripheral (subcutaneous) inoculation 30% (Instituto Nacional de Estudios Sobre Viin rhesus macaques. These non-human primates rosis Hemorragicas, Pergamino. Argentina, unhave been previously shown to develop clinical published data). Effective public health prosyndromes following infection with wild-type grams, together with early administration of strains that closely mimic human AHF. immune plasma obtained from convalescent donors, have effectively reduced the death rate to less than 1 %.`7 However, immunization of the
MATERIALS AND METHODS
at-risk population offers the only practical soIltron for control of the disease.
Attempts to develop a safe and effecive AHF Vaccine strain vaccine have been continuous since the late 1950s: none of these efforts has produced a prodCandid #1 vaccine was derived from an attenuct suitable for widespread human use." Re-uated SMB passage of prototype XJ strain Junin cently, a candidate live-attenuated immunogen virus by single-burst selection in certified fetal was developed using serial suckling mouse brain rhesus lung cells" (Barrera Oro J, Eddy G, un-(SMB) and cell culture passage of prototype XJ published data).
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93-12820 Prior to termination of the studs. all animals All animals were housed in a single room under were challenged with virulent Junin virus to asBiosafetv Level-3 (BL-3) containment.
sess vaccine efficacy (McKee K Jr and others. Macaques were sedated with ketamine hydro-unpublished data). chloride (7 mg/kg/dose) to obtain blood and throat swabs, and for physical examination. Blood
Infectivity assays specimens were obtained from saphenous or femoral veins using a 23-or 21 -gauge butterfly Materials for direct quantitative viral titration needle. Venipuncture sites were cleansed with were assayed by plaquing the virus on Vero cell 70% ethanol before needle insertion. monolayers. as previously described." In conducting the research described in this Peripheral blood mononuclear cells (PBMC) report, the investigators adhered to the Guide fbr were cocultivated with Vero cell monolayc:s to the Care and Use of Laboratory Animals, as facilitate virus recovery. Heparinized whole blood promulgated by the Committee of Laboratory samples were centrifuged. the plasma was deAnimal Resources of the National Research canted, and the cellular elements were layered Council. The facilities are fully accredited by the onto a cushion of histopaque 1077 (Sigma, St. American Association for the Accreditation of Louis, MO) for separation. After the samples were Laboratory Animal Care.
centrifuged at 1,600 x g for 20 min, the visible mononuclear fraction was identified and with-" Experimental design drawn with a pasteur pipette, washed, and resuspended in RPMI 1640 (complete) medium. Animals were assigned randomly to one offive Each of two T-25 flasks containing confluent Vero experimental groups receiving 20-fold dilutions cell monolayers was then inoculated with 5 ml of Candid #1 or placebo ( Table 1) . On day 0, of mononuclear cell suspension, and incubated each macaque received 0.5 ml of vaccine or sa-at 36°C for one week. On the seventh day, the line placebo by subcutaneous injection, accordsupernatants were decanted, and the cells were ing to group assignment.
removed by shaking with glass beads. The cells Macaques were observed at least once a day were resuspended in saline, spotted onto slides. for 106 days for signs ofclinical illness. Objective stained with a fluorescein isothiocyante--conjudisease parameters were monitored three times gated rabbit anti-Junin virus antiserum. and were a week for four weeks after vaccination, and at examined by direct immunofluorescence. Venous blood was collected in glass tubes consupernatant fluid obtained from this centrifutaining EDTA or heparin for hcmatolog) dclirgation was assayed directly by plaquing on Vero minations. White blood cell counts. differcntial cells as described above. All samples were paswhite blood cell counts, and platelet counts %%erc saged blindly in this manner through four cycles obtained using an Ortho ELT-7 hematolog, an-(unless interrupted by contamination) before bealyzer (Ortho Diagnostics, Braintree. MA). ing considered negative for the presence of virus.
Serum biochemical values were measured w ih an Abbott VP analyzer (Abbott Laboratories.
Characteri.zation of iirus isolates
North Chicago, IL). Assay systems using kinetic (rate)-type reactions with commercialls availSelected isolates from the blood of vaccinated able kits were adapted for use on the Abbott animals were identified as Junin virus by neu-analyzer. tralization with a standard monkey serum. This serum (titer = 1:4.096) was collected from a rheStatistical analsis-m sus macaque participating in a separate experiment who received a single inoculation with Data were analyzed on a microcomputer at the Candid #1 strain ofJunin virus. For neutralizing Biometrics L.nd Information Management Divirus isolates in the current study. the serum was vision (USAMRIID) using general linear models diluted 1:5.
(GLM) programs available on SAS (Statistical The potential for in vivo reversion of Candid Analysis System, Cary-. NC) software. Differ-#1 was assessed by examining the virulence of ences among vaccinated groups over time, as selected PBMC isolates for juvenile mice." 11 " well asdifferences between vaccinated groups and Briefly, 11-12-day-old female CD-I strain mice placebo controls, were determined b% repeated (Charles River Breeding Laboratories, Charles measures analysis of variance procedures. River, MA) were inoculated intracerebrally with serial 10-fold dilutions of virus isolates obtained RESULTS by cocultivation of PBMC or control virus strains (0.02 ml/dose). Each isolate also was titrated siClhnicalfindings multaneously by a plaque assay in Vero cells as described above. All inocula were used at similar Following inoculation of Candid #1 or saline low (1-2) cell passage levels. Animals were ob-placebo, all macaques remained generally health,. served daily for 21 days. and 50% lethal dose No evidence of malaise, lethargy. diarrhea. con-(LD,) values were determined by the method of stipation. rash. or mucous membrane hemorReed and Muench.1 6 A Lethal Index (LI) was rhage was found in any animal. Depressed apthen was calculated according to the following petite was noted by a caretaker on days 37 and formula: LI = (log,,,PFU) -(log,,ELD,,). where 39 postvaccination in one macaque who had re-PFU = the number of plaque-forming units ob-ceived 6,360 PFU of Candid #1; food and water tained by Vero cell plaque assay.
intake was unremarkable on all other days. and Virus strains used for comparison in this assay the relationship of this isolated event to immuincluded the Candid #1 vaccine given to manization is unclear. Appetites were normal in all caques and the XJ Clone 3 (SMB passage 1) at-other macaques throughout the study. tenuated Junin virus strain.
Mean body weights decreased slightly from baseline levels in all groups (including placebo) Serology during the initial 10 days after vaccination, possibly as a function oftheir having been trequently Neutralizing antibodies were measured against manipulated ( Figure IA) . The weights then in-XJ Clone 3 Junin virus by a constant virus. se-creased in all groups, although to a lesser degree rum dilution, plaque reduction technique as pre-in the animals receiving the two highest vaccine viously described.'. " Endpoints were recorded doses. However, in no case was weight loss obas the highest dilution yielding -f 80% reduction served to be ofany physiologic significance. Recin plaque number.
tal temperatures varied widely, and were higher /1IhA~
in all groups (including placebo) after vaccina-(12% positive). Isolates were recovered from 14 tion ( Figure 1B) ; however, the magnitude of this (70%) of 20 vaccinated macaques between one change was not statistically or biologically sig-and 21 days after immunization: 23 (85%) of the nificant. and perhaps was another reflection of 27 were made between days 4 and 14. In the the extensive manipulation of these animals.
group receiving the highest vaccine dose ( 127.200 PFU), isolations werte made from three consecClinical laboratory studies utive bleeds over one week in three of five animals. from two consecutive bleeds in one animal. Levels of the following parameters were de-and on a single occasion in the remaining matermined in sequential serum samples obtained caque. Repeated isolations from the same animal from all animals before and after immunization were made once in the group receiving 6.360 with Candid #1 or placebo: sodium, potassium, PFU, and twice in each of the two groups rechloride, total protein, albumin, glucose. urea ceivinglower doses. In contrast, C(ndid #1 could nitrogen, creatinine, calcium, magnesium. cho-be recovered only twice from 225 plasma samlesterol. triglycerides, total bilirubin. amylase.
pies (0.9%) by direct plaquing during the same aspartate aminotransferase. alanine amino-period (Table 2 ). Both plasma isolates were obtransferase. alkaline phosphatase, alpha hy-tained from two animals in whom PB:MC were droxybutyrate dehydrogenase. gamma-glutasimultaneously positive for virus. Neither plasmyl transpeptidase. lactate dehydrogenase.
ma-nor PBMC-associated viremia was observed creatine kinase, total IgG, IgM, and IgA; and in the presence of neutralizing antibody in an% complement factors 3 and 4. Only four of the macaque at any time. 26 parameters measured (sodium, potassium, Virus could not be recovered by direct plaurea nitrogen, and IgM) exhibited overall treat-quing of oropharyngeal swabs obtained at the ment effects by GLM repeated measures analtime animals were bled. However. amplification ysis. In all cases, observed effects could be dis-ofcultures on Vero cell monolayers overlaid with counted as normal variation (compared with liquid media for one week yielded a small numpooled control and day 0 values), prevaccinaber of plaques (titer ý 1.68 Iog,,, PFU mli) on tion differences (significant differences were ob-assay of culture supernatants from the da%. 10-served only for day 0 values), or possible lab-sample of one macaque. This animal was a memoratory error (lower lgM in the group receiving ber of the group receiving the highest concentra-318 PFU of Candid #1 than in the group re-tion of vaccine (127,200 PFU). and Junin virus ceiving 16 PFU).
was recovered from PBMC. but not from plasma. Samples for clinical hematologic analysis were on the same day. No additional isolations were inadvertently collected into tubes containing made by amplification of specimens from any heparin instead of EDTA for the first two days other animals on any other days. on which specimens were obtained (days 0 and 4). Although total white blood cell, absolute neuCharacterization of isolates trophil, and platelet counts were mildly decreased on these two days when compared with Neutralization of 24 (89%) of 27 viruses resubsequent values, statistically significant differ-covered by cocultivation of PBMC. and both ences were seen only for neutrophils (P = 0.02, plasma isolates, was performed against a stanby repeated measures analysis of variance); ab-dard Candid #1 immune monkey serum. In all solute lymphocyte counts and packed cell volbut four cases, complete neutralization (from 2.49 umes (hematocrit) were not affected. No other to 6.42 log,( PFU) was accomplished; in the resignificant effects were observed for the remainmainder, the reduction in titer was > 99.95% der of the 28-day sampling period.
(4.83-5.32 log,,) PFU neutralized) ( Table 3) . Eleven of the 27 PBMC isolates that were colVirus isolation lected from animals 7-21 days after immunization and were representative of each vacciRecovery of virus from blood by cocultivation nation group were evaluated for their virulence of PBMC was attempted in all animals after im-in 1 I-1 2-day-old juvenile mice (Table 4) . Five munization ( Table 2) . Twenty-seven Candid #1
isolates were less virulent than the parent vaccine isolates were obtained from 223 PBMC samples (11 > 3.62). and all were less virulent than the Serology, individual animals. Antibodies were initially detected on day 14 in two macaques that received Neutralizing antibodies were detected in all the highest vaccine dose (Figure 2 ). The highest macaques inoculated with Candid #1 at some antibody titers were also achieved in animals from this group (maximum geometric mean titer macaques infected with wild-type Junin virus [GMT]= 1:1,176 on day 56). Antibodies were strains."' These results suggest that Candid #1 not seen until days 17-24 in macaques receiving is relatively limited in its ability to replicate in lower doses, but tended to reach the same maxvivo. and is unlikely to spread among individimum level (maximum GMT = 1:84-1:128 on uals. In previous studies involving wild-type day 106). No seroconversions occurred among Junin virus strains, cross-contamination of plaplacebo recipients, cebo controls housed in the same room was freThe time from initial recovery of virus from quently seen.'(McKee K Jr. unpublished data).
PBMC to detection of neutralizing antibodies
No infection of placebo-inoculated macaques ocvaried from seven to 39 days. However, it should curred in the present experiment. be noted that antibodies were not measured for Candid #1 could be recovered from monoan entire month following the day 28-bleed. Thus, nuclear cells in the peripheral circulation for up for the 12 animals in whom virus was recovered to three weeks after immunization. While most early enough to allow for accurate assessment of isolates were made from animals that received the interval to seroconversion (i.e., during the the highest vaccine doses, it was possible to refirst 10-14 days after vaccination), II seroconcover virus from animals in every dose group. vetted 1-2.5 weeks after initial virus recovery.
That the viruses recovered were Junin virus is certain: all isolates tested (89% of those recov-DISCUSSION ered) were specifically neutralized by a primate antiserum produced by a single inoculation with This placebo-controlled study demonstrated Junin virus. This antiserum. although raised to that Candid #1, a recently developed live-atten-Candid #1 itself, is unlikely to have inappropriuated Junin virus vaccine, is safe and immu-ately detected an adventitious agent. Candid #1 nogenic in nonhuman primates. At doses from was prepared and tested in a laboratory, suite 16 to 127,200 PFU (a four log,,, range), there was specifically designated for vaccine production; no significant effect of immunization on any no other viruses were manipulated in the labophysical, hematologic, or biochemical parameter ratory during this period. Subsequently, an exmeasured. Moreover, even at the lowest dose tensive battery of in vivo and in vitro tests failed tested, 100% of the animals inoculated respondto detect any evidence of contamination. An aned with detectable neutralizing antibodies. tiserum raised against another Junin virus strain. The infrequent recovery of virus from plasma grown .nder general laboratory conditions and and the virtual absence of virus in oropharyngeal in the absence of the stringent laboratory controls swabs contrasts sharply with findings in rhesus used in the culture of candidate vaccines, would
FIGURE 2. Neutralizing antibody response in rhesus macaques inoculated with graded doses of Candid -I vaccine. Values represent geometric mean titers for animals within each dose group. PFU = plaque-forming units.
have been much more likely to contain antibod-tibodies did not coexist in any animal suggests ies against an undetected adventitious agent.
that antibody plays a major role in virus clearTherefore, use of such a strain could have con-ance. That this is true has been demonstrated in fused the identity of viruses recovered from an-the elegant therapeutic studies of Maiztegui and imals in these experiments, others' and Enria and others.' in which human Although lethality and disease patterns have immune plasma containing sufficient neutralizbeen associated with certain wild-type Junin vi-ing antibody was administered to patients with rus strains in animal models, no specific bio-AHF within eight days of disease onset, and rechemical or antigenic markers for virulence have suited in prompt clearance of virus and a signifyet been identified. "1. 18 Thus, assessments of rel-icant reduction in mortality. However, it is evative virulence among attenuated strains must ident that other, as yet undefined, factors are also be made in biological systems of sufficient senoperative in virus clearance. In the present study. sitivity to detect reproducible differences. Preboth plasma-and PBMC-associated viremia ofvious reports have indicated that 11-1 4-day-old ten disappeared well before the appearance of mice are useful in distinguishing virulent from antibody (up to several weeks). It should also be attenuated Junin virus strains.'-4. '1 Typically, noted that viremia and circulating antibody frelethal indices for wild-type strains in this mouse quently coexist in Lassa fever, a related human assay are << 1.00. In contrast, the previously arenavirus infection, and neutralization of virus tested human vaccine candidate, XJ Clone 3. has using in vitro techniques similar to that for Junin been repeatedly shown to be significantly more virus is difficult." Clearly, the mechanisms of in attenuated than wild-type strains (LI 1.25). When vivo neutralization and virus clearance are comwe used this system to examine viruses recovered plex and multi-factorial. from the blood of Candid #1-vaccinated maDespite the fact that antibodies were found in caques, we found no evidence of in vivo rever-every vaccinated animal, the absolute levels obsion, all tested isolates (each ofwhich previously served in some animals were relatively unimhad been documented as Junin virus) had an 1, pressive. In one macaque vaccinated with 318 in 11-12-day-old mice similar to that of the in-PFU, antibodies were detected only on day 56 oculum (and higher than that for the XJ Clone at a serum dilution of 1:8. Similarly, antibodies 3 attenuated control), were detected only once at a titer of 1:32 in two Our finding that viremia and neutralizing ananimals (one each receiving 16 PFLJ and 318
